2024
Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era
Lee D, McNamara M, Yang A, Yaskolko M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Pigment Cell & Melanoma Research 2024, 37: 847-853. PMID: 39073002, DOI: 10.1111/pcmr.13188.Peer-Reviewed Original ResearchSite of metastasisPattern of metastatic diseaseMelanoma mortalityRetrospective observational cohort studyCause of cancer mortalityDistant lymph nodesObservational cohort studyDiagnosis to deathImmunotherapy eraAdvanced melanomaMetastatic diagnosisMetastatic diseaseMetastatic melanomaImmunotherapy treatmentRespiratory failureCause of deathMedian timeLymph nodesTherapeutic advancesCohort studyMelanomaImmunotherapyMechanism of deathPatientsEnd of lifeCauses of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era.
Lee D, Yang A, McNamara M, Kluger H, Tran T, Olino K, Clune J, Sznol M, Ishizuka J. Causes of death and patterns of metastatic disease at the end of life for patients with advanced melanoma in the immunotherapy era. Journal Of Clinical Oncology 2024, 42: e21522-e21522. DOI: 10.1200/jco.2024.42.16_suppl.e21522.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsYale Cancer CenterAdvanced melanomaMetastatic diseaseMetastatic melanomaRespiratory failureSite of metastatic diseasePattern of metastatic diseaseDied of respiratory failureAnti-CTLA4 treatmentRetrospective observational cohort studyAnti-PD1 therapyDistant lymph nodesPatients aged >Site of diseaseSurvival of patientsObservational cohort studyMulti-system involvementDiagnosis to deathImmunotherapy eraAnti-PD1Checkpoint inhibitorsInstitutional review boardMetastatic sitesMetastatic diagnosisDigital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma
Su D, Schoenfeld D, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm D, Khan S, Halaban R, Kluger H, Olino K, Galan A, Clune J. Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma. Journal For ImmunoTherapy Of Cancer 2024, 12: e008646. PMID: 38519058, PMCID: PMC10961546, DOI: 10.1136/jitc-2023-008646.Peer-Reviewed Original ResearchConceptsCTLA-4 expression levelsCancer-associated fibroblastsAssociated with worse survivalExpression of immune checkpointsLAG-3 expressionDesmoplastic melanomaLymphoid aggregatesCTLA-4PD-1Immune checkpointsIntratumoral leukocytesLAG-3Tumor compartmentsWorse survivalCD20+B cellsIncreased expression of immune checkpointsProgrammed cell death protein 1Macrophage/monocyte markerSentinel lymph node positivityCell death protein 1Associated with poor prognosisLymph node positivityDense fibrous stromaPotential prognostic significanceCore of tumorsImmunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitorsImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2023
The Facial Artery Perforator Flap
Lewis K, Islam S, Phillips S, Carney M, Clune J. The Facial Artery Perforator Flap. Journal Of Craniofacial Surgery 2023, 34: e434-e437. PMID: 36914599, DOI: 10.1097/scs.0000000000009249.Peer-Reviewed Original ResearchConceptsArtery perforator flapPerforator flapFacial artery perforator flapPositive marginsNasolabial foldsDonor site morbidityAverage followFinal pathologyLocal perforator flapsPathologic evidenceExcisional marginsRetrospective reviewNegative marginsPathology resultsImmediate reconstructionLess dissectionFlap elevationMelanoma casesAverage ageFacial arteryPatientsSite morbidityLarge flapNasal sidewallSenior author
2020
Upper Extremity Variations
Kim S, Xu X, Clune J, Narayan D. Upper Extremity Variations. 2020, 375-418. DOI: 10.1007/978-3-030-55660-0_17.Peer-Reviewed Original ResearchFlexor digitorum superficialisMedian nerveFlexor retinaculumFlexor carpi radialis tendonFlexor digitorum profundusMotor branchCutaneous branchBrachial arteryMedial cordThenar musclesBrachial plexusCubital fossaUlnar arteryRadial headPronator teresBicipital aponeurosisRadial halfPalmar aspectNerveArteryThird fingerSuperficialisFourth fingerRetinaculumFossaUpper and Lower Extremity Vascular Variations
Xu X, Kim S, Clune J, Narayan D. Upper and Lower Extremity Vascular Variations. 2020, 437-466. DOI: 10.1007/978-3-030-55660-0_19.Peer-Reviewed Original Research
2016
Functional Neck Dissection
Patel A, Clune J, Ariyan S. Functional Neck Dissection. Plastic & Reconstructive Surgery 2016, 138: 1084-1086. PMID: 27783008, DOI: 10.1097/prs.0000000000002705.Peer-Reviewed Original ResearchThumb Amputations in Children
Jones N, Clune J. Thumb Amputations in Children. Hand 2016, 11: 77s-77s. DOI: 10.1177/1558944716660555en.Peer-Reviewed Original ResearchMultiple finger amputationsThumb amputationToe-to-thumb transfersIsolated thumb amputationsFinger amputationsLevel of amputationProximal phalanxToe transferTraumatic amputationBilateral thumb amputationsGreat toe transferAmputationHead of the proximal phalanxCarpometacarpal jointHand surgeonsToeOlder childrenSoft tissue coverageGrasping functionChildrenYoung childrenCarpometacarpalSecond toe transferThumbReverse radial forearm flapMalignant Melanoma
Pavri SN, Clune J, Ariyan S, Narayan D. Malignant Melanoma. Plastic & Reconstructive Surgery 2016, 138: 330e-340e. PMID: 27465194, DOI: 10.1097/prs.0000000000002367.Peer-Reviewed Original ResearchConceptsWide local excisionSentinel lymph node biopsyLymph node biopsySentinel lymphLocal excisionAuricular melanomaNode biopsyMedical therapyMetastatic melanomaSubungual melanomaMalignant melanomaDesmoplastic melanomaNational Comprehensive Cancer Network guidelinesIntermediate-thickness melanomasPostoperative radiation therapyGold standardHigh-risk lesionsCutaneous malignant melanomaFull-thickness skinThickness melanomaPregnant patientsInitial managementPreoperative lymphoscintigraphySurgical treatmentOngoing trials
2011
Surgical Reconstruction in Melanoma
Clune JE, Narayan D. Surgical Reconstruction in Melanoma. Current Problems In Cancer 2011, 35: 185-199. PMID: 21911182, DOI: 10.1016/j.currproblcancer.2011.07.006.Peer-Reviewed Original ResearchExcising Value at a Marginal Cost: Rethinking the Management of Basal Cell Carcinoma
Patel A, Clune JE, Mody P, Price G, Ariyan S. Excising Value at a Marginal Cost: Rethinking the Management of Basal Cell Carcinoma. Plastic & Reconstructive Surgery 2011, 127: 2136-2137. PMID: 21532456, DOI: 10.1097/prs.0b013e31820e9405.Peer-Reviewed Original ResearchAutologous cranial particulate bone graft: an experimental study of onlay cranioplasty.
Clune JE, Mulliken JB, Glowacki J, Arany PR, Kulungowski AM, Rogers GF, Greene AK. Autologous cranial particulate bone graft: an experimental study of onlay cranioplasty. The Journal Of Craniofacial Surgery 2011, 22: 319-23. PMID: 21239926, DOI: 10.1097/SCS.0b013e3181f7e0e2.Peer-Reviewed Original Research
2010
Inlay cranioplasty: an experimental comparison of particulate graft versus bone dust.
Clune JE, Mulliken JB, Glowacki J, Rogers GF, Arany PR, Kulungowski AM, Greene AK. Inlay cranioplasty: an experimental comparison of particulate graft versus bone dust. Plastic And Reconstructive Surgery 2010, 126: 1311-1319. PMID: 20885252, DOI: 10.1097/PRS.0b013e3181ea4524.Peer-Reviewed Original ResearchPerioperative corticosteroid reduces hospital stay after fronto-orbital advancement.
Clune JE, Greene AK, Guo CY, Gao LL, Kim S, Meara JG, Proctor MR, Mulliken JB, Rogers GF. Perioperative corticosteroid reduces hospital stay after fronto-orbital advancement. The Journal Of Craniofacial Surgery 2010, 21: 344-8. PMID: 20186083, DOI: 10.1097/SCS.0b013e3181cf6103.Peer-Reviewed Original Research
2009
Nipple adenoma in infancy.
Clune JE, Kozakewich HP, VanBeek CA, Labow BI, Greene AK. Nipple adenoma in infancy. Journal Of Pediatric Surgery 2009, 44: 2219-22. PMID: 19944237, DOI: 10.1016/j.jpedsurg.2009.08.020.Peer-Reviewed Original Research